Rare and very rare adverse effects of clozapine

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 1995-2003

  De Fazio, Pasquale ^a   Gaetano, Raffaele ^a   Caroleo, Mariarita ^a   Cerminara, Gregorio ^a   Maida, Francesca ^a   Bruno, Antonio ^b   Muscatello, Maria Rosaria ^b   Moreno, Maria Jose Jaén ^c   Russo, Emilio ^a   Segura García, Cristina ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

Atypical antipsychotic; Clozapine; Rare adverse effects; Schizophrenia

Indexed keywords

CLOZAPINE;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADVERSE OUTCOME; ANGIONEUROTIC EDEMA; BLISTER; CARDIOMYOPATHY; COLON PERFORATION; CONGESTIVE CARDIOMYOPATHY; CONSTIPATION; DEPRESSION; DIABETES MELLITUS; DIZZINESS; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG WITHDRAWAL; DYSLIPIDEMIA; EARLY DIAGNOSIS; EPILEPSY; ERYTHEMA; FAINTNESS; FEVER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY DISORDER; HEADACHE; HEMATEMESIS; HIGH RISK PATIENT; HUMAN; HYPERSALIVATION; HYPOTENSION; IMPOTENCE; INTERTRIGINOUS ERYTHEMA; INTESTINE ISCHEMIA; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; ISCHEMIC COLITIS; LIVER DISEASE; LIVER FAILURE; LUNG EMBOLISM; NAUSEA; OGILVIE SYNDROME; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PARALYTIC ILEUS; PAROTITIS; PERICARDITIS; PERIORBITAL EDEMA; PHEOCHROMOCYTOMA; PITYRIASIS ROSEA; PRIAPISM; PSYCHOSIS; RASH; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; STEVENS JOHNSON SYNDROME; TACHYCARDIA; TOXIC EPIDERMAL NECROLYSIS; TREMOR; URINE INCONTINENCE; VERTIGO; VISUAL DISORDER; XEROSTOMIA;

EID: 84938865795     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S83989     Document Type: Review

References (101)

1. Stahl S. Essential Psychopharmacology. Neuroscientific Basis and Practical Applications (Essential Psychopharmacology Series). Cambridge: Cambridge University Press; 2008.
2. Indanpaan-Heikkila J, Alhava E, Olkinuora M, Palva IP. Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol. 1977;11(3):193-198.
3. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-796.
4. Solanki RK, Singh P, Munshi D. Current perspectives in the treatment of resistant schizophrenia. Indian J Psychiatry. 2009;51(4):254-260.
5. Taylor S. Electroconvulsive therapy: a review of history, patient selection, technique, and medication management. South Med J. 2007;100(8):494-498.
6. Malhotra AK. Pharmacogenomics and schizophrenia: clinical implications. Pharmacogenomics J. 2001;1(2):109-114.
7. Kane J, Honigfeld G, Singer J, Melzer H; the Clozaril Collaborative Study Group. Clozapine for treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine/benztropine. Arch Gen Psychiatry. 1998;45(9):789-796.
8. Gareri P, De Fazio P, Russo E, Marigliano N, De Fazio S, De Sarro G. The safety of clozapine in the elderly. Expert Opin Drug Saf. 2008;7(5):525-538.
9. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry. 2008;63(5):524-529.
10. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999;25(2):233-255.
11. Lindenmayer JP, Iskander A, Park M, et al. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J Clin Psychiatry. 1998;59(10):521-527.
12. Brar JS, Chengappa KN, Parepally H, et al. The effects of clozapine on negative symptoms in patients with schizophrenia with minimal positive symptoms. Ann Clin Psychiatry. 1997;9(4):227-234.
13. Gareri P, De Fazio P, De Fazio S, Norma Marigliano N, Ferreri Ibbadu G, De Sarro G. Adverse effects of atypical antiphychotics in the elderly. Drugs Aging. 2006;23(12):937-956.
14. Melzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989;251(1):238-246.
15. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry. 2001;158(3):360-369.
16. Song C, Lin A, Kenis G, Bosmans E, Maes M. Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr Res. 2000;42(2):157-164.
17. Paterson GJ, Ohashi Y, Reynolds GP, Pratt JA, Morris BJ. Selective increases in the cytokine, TNFalpha, in the prefrontal cortex of PCP-treated rats and human schizophrenic subjects: influence of antipsychotic drugs. J Psychopharmacol. 2006;20(5):636-642.
18. Gross A, Joffe G, Joutsiniemi SL, Nyberg P, Rimón R, Appelberg B. Decreased production of reactive oxygen species by blood monocytes caused by clozapine correlates with EEG slowing in schizophrenic patients. Neuropsychobiology. 2003;47(2):73-77.
19. Cohen SA, Underwood MT. The use of clozapine in a mentally retarded and aggressive population. J Clin Psychiatry. 1994;55(10):440-444.
20. Friedman JH. Parkinson disease psychosis: update. Behav Neurol. 2013;27(4):469-477.
21. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology. 1997;8(6):671-677.
22. Krupp P, Barnes P. Clozapine-associated agranulocytosis: risk and aetiology. Br J Psychiatry Suppl. 1992;17:38-40.
23. Young CR, Bowers MB, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull. 1998;24(3):381-390.
24. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ. 2005;172(13):1703-1711.
25. Farmaciemedici.it [homepage on the Internet]. A.I.F.A. [updated June 6, 2014]. Available from: http://www.farmaciemedici.it/farmaci/bugiardino/leponex/aifa/. Accessed February 19, 2015.
26. Kamphuis H, Arends J, Timmerman L, van Marle J, Kappert J. Myocarditis and cardiomyopathy: underestimated complications resulting from clozapine therapy. Tijdschr Psychiatr. 2010;52(4):223-233.
27. Crews MP, Dhillon GS, MacCabe JH. Clozapine rechallenge following clozapine-induced pericarditis. J Clin Psychiatry. 2010;71(7):959-961.
28. Rathore S, Masani ND, Callaghan PO. Clozapine-induced effuso-constrictive pericarditis. Case report and review of the literature. Cardiology. 2007;108:183-185.
29. Alawami M, Wasywich C, Cicovic A, Kenedi C. A systematic review of clozapine induced cardiomyopathy. Int J Cardiol. 2014;176(2):315-320.
30. Lamberti JS, Olson D, Crilly JF, et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry. 2006;163(7):1273-1276.
31. Safferman A, Lieberman J, Kane J, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull. 1991;17(2):247-261.
32. Naheed M, Green B. Focus on clozapine. Curr Med Res Opin. 2001;17(3):223-229.
33. Velayudhan R, Kakkan S. Late onset clozapine induced agranulocytosis. Indian J Psychol Med. 2014;36(4):425-427.
34. Alvir JM, Lieberman JA. Agranulocytosis: incidence and risk factors. J Clin Psychiatry. 1994;55(suppl B):137-138.
35. Laker M, Cookson J. Reflux oesophagitis and clozapine. Int Clin Psychopharmacol. 1997;12(1):37-39.
36. Townsend G, Curtis D. Case report: rapidly fatal bowel ischaemia on clozapine treatment. BMC Psychiatry. 2006;6:43.
37. Rege S, Lafferty T. Life-threatening constipation associated with clozapine. Australas Psychiatry. 2008;16(3):216-219.
38. Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry. 2008;69(5):759-768.
39. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry. 1994;151(12):1744-1752.
40. Hayes G, Gibler B. Clozapine-induced constipation (letter). Am J Psychiatry. 1995;152(2):298.
41. Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients. J Clin Psychiatr. 2004;65(suppl 2):5-99.
42. Holzer P, Ahmedzai SH, Niederle N, et al. Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. J Opioid Manag. 2009;5(3):145-151.
43. Baker DE. Methylnaltrexone bromide: new drug for the treatment of opioid induced bowel dysfunction. Rev Gastroenterol Disord. 2009;9(3):E84-E93.
44. Onali P, Olianas MC. N-Desmethylclozapine, a major clozapine metabolite, acts as a selective and efficacious delta-opioid agonist at recombinant and native receptors. Neuropsychopharmacology. 2007;32(4):773-785.
45. Tomer T, Jonathan B, Alan M. Death from clozapine-induced constipation: case report and literature review. Psychosomatics. 2002;43(1):71-73.
46. Van Soest E, Dieleman J, Kuipers E. The effect of anticholinergic agents on gastrooesophageal reflux and related disorders. Expert Opin Drug Saf. 2008;7(2):173-180.
47. Praharaj SK, Arora M, Gandotra S. Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology (Berl). 2006;185(3):265-273.
48. Baker RW, Chengappa KN. Gastroesophageal reflux as a possible result of clozapine treatment. J Clin Psychiatry. 1998;59(5):257.
49. van Veggel M, Olofinjana O, Davies G, Taylor D. Clozapìne and gastro-oesophageal reflux disease (GORD) - an investigation of temporal association. Acta Psychiatr Scand. 2012;127(1):69-77.
50. Taylor D, Olofinjana O, Rahimi T. Use of antacid medication in patients receiving clozapine: a comparison with other second generation antipsychotics. J Clin Psychopharmacol. 2010;30(4):460-461.
51. de Bruin GJ, Bac DJ, van Puijenbroek EP, van der Klooster JM. Ogilvie Syndrome induced by clozapine. Ned Tijdschr Geneeskd. 2009;153:B437.
52. Saunders MD, Kimmey MB. Systematic review: acute colonic pseudo-obstruction. Aliment Pharmacol Ther. 2005;22(10):917-925.
53. Dworkin RH. Pain insensitivity in schizophrenia: a neglected phenomenon and some implications. Schizophr Bull. 1994;20(2):235-248.
54. Bickerstaff LK, Harris SC, Leggett RS, Cheah KC. Pain insensitivity in schizophrenic patients. A surgical dilemma. Arch Surg. 1988;123(1):49-51.
55. Rosenthal SH, Porter KA, Coffey B. Pain insensitivity in schizophrenia. Case report and review of the literature. Gen Hosp Psychiatry. 1990;12(5):319-322.
56. Potvin S, Stip E, Tempier A, et al. Pain perception in schizophrenia: no changes in diffuse noxious inhibitory controls (DNIC) but a lack of pain sensitization. Psychiatr Res. 2008;42(12):1010-1016.
57. Keoghane SR, Sullivan ME, Miller MA. The aetiology, pathogenesis and management of priapism. BJU Int. 2002;90(2):149-154.
58. Reif R, Výborný K. Priapism: a urological emergency. Acta Univ Palacki Olomuc Fac Med. 1993;135:59-63.
59. Compton MT, Miller AH. Sexual side effects associated with conventional and atypical antipsychotics. Psychopharmacol Bull. 2001;35(3):89-108.
60. Seftel A, Saenz de Tejada I, Szetela B, Cole J, Goldstein I. Clozapine-associated priapism: a case report. J Urol. 1992;147(1):146-148.
61. Mulhall JP, Kaminetsky JC, Althof SE, et al. Correlations with satisfaction measures in men treated with phosphodiesterase inhibitors for erectile dysfunction. Am J Mens Health. 2011;5(3):261-271.
62. Hanes A, Lee Demler T, Lee C, Campos A. Pseudoephedrine for the treatment of clozapine-induced incontinence. Innov Clin Neurosci. 2013;10(4):33-35.
63. Harrison-Woolrych M, Skegg K, Ashton J, Herbison P, Skegg DC. Nocturnal enuresis in patients taking clozapine, risperidone, olanzapine, and quetiapine: comparative cohort study. Br J Psychiatry. 2011;199(2):140-144.
64. Lin CC, Bai YM, Chen JY, Lin CY, Lan CY, Lan TH. A retrospective of clozapine and urinary incontinence in Chinese in-patients. Acta Psychatr Scand. 1999;100(2):158-161.
65. Fuller MA, Borovicka MC, Jaskiw GE, Simon MR, Kwon K, Konicki PE. Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. J Clin Psychiatry. 1996;57(11):514-518.
66. Warner JP, Harvey CA, Barnes TR. Clozapine and urinary incontinence. Int Clin Psychopharmacol. 1994;9(3):207-209.
67. Thor KB, Donatucci C. Central nervous system control of the lower urinary tract: new pharmacological approaches to stress urinary incontinence in women. J Urol. 2004;172(1):27-33.
68. Clark N. Conventional antipsychotic and clozapine-induced urinary incontinence. J Coll Psychiatr Neurolog Pharma. 2003;2:1-8.
69. Mishra B, Sahoo S, Sarkar S, Akhtar S. Clozapine-induced angioneurotic edema. Gen Hosp Psychiatry. 2007;29(1):78-80.
70. Lai YW, Chou CY, Shen WW, Lu ML. Pityriasis rosea-like eruption associated with clozapine: a case report. Gen Hosp Psychiatry. 2012;34:e5-e7.
71. Rao A, Francis N, Morar N. Clozapine-induced symmetrical drug-related intertriginous and flexural exanthema: first reported cases. Br J Dermatol. 2012;166(5):1142-1143.
72. Srihari VH, Lee TW. Pulmonary embolism in a patient taking clozapine. BMJ. 2008;336(7659):1499-1501.
73. Tripp AC. Non-fatal pulmonary embolus associated with clozapine treatment: a case series. Gen Hosp Psychiatry. 2011;33(1):e5-e6.
74. Joksovic PM, Chiles C. Cardiac arrest and pulmonary embolism after clozapine titration. Prim Care Companion CNS Disord. 2011;13(2):MC3184584.
75. Munoli RN, Praharaj SK, Bhat SM. Clozapine-induced recurrent pulmonary thromboembolism. J Neuropsychiatry Clin Neurosci. 2013;25(3):E50-E51.
76. Hägg S, Jönsson AK, Spigset O. Risk of venous thromboembolism due to antipsychotic drug therapy. Expert Opin Drug Saf. 2009;8(5):537-547.
77. Paciullo CA. Evaluating the association between clozapine and venous thromboembolism. Am J Health Syst Pharm. 2008;65(19):1825-1829.
78. Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet. 2000;356(9237):1219-1223.
79. Parkin L, Skegg DC, Herbison GP, Paul C. Psychotropic drugs and fatal pulmonary embolism. Pharmacoepidemiol Drug Saf. 2003;12(8):647-652.
80. Davidson M, Kahn RS, Stern RG, et al. Treatment with clozapine and its effect of plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Res. 1993;46(2):151-163.
81. Breier A, Buchanan RW, Waltrip RW, Listwak S, Holmes C, Goldstein DS. The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy. Neuropsychopharmacology. 1994;10(1):1-7.
82. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH. Clinical and biologic response to clozapine in patients with schizophrenia: Cross-over comparison with fluphenazine. Arch Gen Psychiatry. 1992;49(5):345-353.
83. Walther MM, Keiser HR, Linehan WM. Pheochromocytoma: evaluation, diagnosis, and treatment. World J Urol. 1999;17(1):35-39.
84. Krentz AJ, Mikhail S, Cantrell P, Hill GM. Pseudophaeochromocytoma syndrome associated with clozapine. BMJ. 2001;322(7296):1213.
85. Li JK, Yeung VT, Leung CM, et al. Clozapine: a mimicry of phaeochromocytoma. Aust NZ J Psychiatry. 1997;31(6):889-891.
86. Prasad SE, Kennedy HG. Pseudophaeochromocytoma associated with clozapine treatment. Ir J Psych Med. 2003;20:132-134.
87. Akinsola O, Ong K. Pseudophaeochromocytoma associated with Clozapine Therapy: a case report. Afr J Psychiatry. 2011;14(5):406-408.
88. Durst R, Raskin S, Katz G, Zislin J, Durst R. Pedal edema associated with clozapine use. Isr Med Assoc J. 2000;2(6):485-486.
89. Sockalingam S, Shammi C, Remington G. Clozapine-induced hypersalivation: a review of treatment strategies. Can J Psychiatry. 2007;52(6):377-384.
90. Brodkin E, Pelton G, Price L. Treatment of clozapine-induced parotid gland swelling. Am J Psychiatry. 1996;152(3):445.
91. Robinson D, Fenn H, Yesavage J. Possible association of parotitis with clozapine. Am J Psychiatry. 1995;152(2):297-298.
92. Brooks KG, Thompson DF. A review and assessment of drug-induced parotitis. Ann Pharmacother. 2012;46(12):1688-1699.
93. Immadisetty V, Agrawal P. A successful treatment strategy for clozapine-induced parotid swelling: a clinical case and systematic review. Ther Adv Psychopharmacol. 2012;2(6):235-239.
94. Reinstein M, Sirotovskya L, Chasonov M. Comparative efficacy and tolerability of benzatropine and terazosin in the treatment of hypersalivation secondary to clozapine. Clin Drug Investig. 1999;17:97-102.
95. Conley RR, Kelly DL. Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Isr J Psychiatry Relat Sci. 2005;42(1):51-60.
96. Théret L, Germail ML, Burde A. Current aspects of the use of clozapine in the Chalons-surMarn Psychiatric Hospital: intestinal occlusion with clozapine. Ann Med Psychol. 1995;153(7):474-477.
97. Drew L, Herdson P. Clozapine and constipation: a serious issue. Aust NZ J Psychiatry. 1997;31(1):149-150.
98. Shammi CM, Remington G. Clozapine-induced necrotizing colitis. J Clin Psychopharmacol. 1997;17(3):230-232.
99. Levin TT, Barrett J, Mendelowitz A. Death from clozapine-induced constipation: a case report and literature review. Psychosomatics. 2002;43(1):71-73.
100. Ferslew KE, Hagardorn AN, Harlan GC, McCormick WF. A fatal drug interaction between clozapine and fluoxetien. J Forensic Sci. 1998;43(5):1082-1085.
101. Flanagan RJ, Ball RY. Gastrointestinal hypomobility: an under-recognised life-threatening adverse effect of clozapine. Forensic Sci Int. 2011;206(1-3):e31-e36.